Serious adverse events · patients with hip osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life · patients with osteoarthritis
1 finding from 1 review
Number withdrawn due to adverse events · patients with osteoarthritis
Celecoxib showed no clear difference in number withdrawn due to adverse events compared with tNSAIDs (low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether celecoxib changes number experiencing any serious adverse events compared with tNSAIDs (very low certainty).
1 finding from 1 review
Number experiencing gastro‐intestinal events (perforation, ulcer, bleeds) · patients with osteoarthritis
It is very uncertain whether celecoxib changes number experiencing gastro‐intestinal events (perforation, ulcer,… compared with tNSAIDs (very low certainty).
1 finding from 1 review
Cardiovascular events (myocardial infarction, stroke) · patients with osteoarthritis
It is very uncertain whether celecoxib changes number experiencing cardiovascular events (myocardial infarction,… compared with tNSAIDs (very low certainty).
1 finding from 1 review
Pain · patients with osteoarthritis
1 finding from 1 review
Physical function · patients with osteoarthritis
1 finding from 1 review
Physical function · patients with rheumatoid arthritis
1 finding from 1 review
Cardiovascular events (myocardial infarction, stroke) · patients with rheumatoid arthritis
Celecoxib showed no clear difference in cardiovascular events (myocardial infarction, stroke) compared with traditional NSAIDs (low certainty).
1 finding from 1 review
Incidence of gastroduodenal ulcers ≥ 3 mm · patients with rheumatoid arthritis
Celecoxib probably leads to lower incidence of gastroduodenal ulcers ≥ 3 mm compared with traditional NSAIDs (moderate certainty).
1 finding from 1 review
Short‐term serious adverse events · patients with rheumatoid arthritis
Celecoxib showed no clear difference in short‐term serious adverse events compared with traditional NSAIDs (low certainty).
1 finding from 1 review
Total number of withdrawals · patients with rheumatoid arthritis
Celecoxib probably leads to lower total withdrawals; compared with traditional NSAIDs (moderate certainty).
1 finding from 1 review
Clinical improvement: American College of Rheumatology 20% improvement criteria (ACR20) · patients with rheumatoid arthritis
Celecoxib showed no clear difference in clinical improvement: American College of Rheumatology 20%… compared with traditional NSAIDs (moderate certainty).
1 finding from 1 review
Pain A 0 t o 100 visual or numerical scale, where 0 equals no pain at all and 100 is the worst pain imaginable · patients with rheumatoid arthritis
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients undergoing knee arthroscopy
3 findings from 1 review
no estimate extracted
2 studies · 80 participants
Very low
no estimate extracted
2 studies · 80 participants
Low
no estimate extracted
2 studies · 80 participants
Low
Analgesia durationTime duration from the end of surgery to the time of first analgesic consumption. Scale from: 0 to 100. · patients undergoing knee arthroscopy
1 finding from 1 review
Adverse eventsPercentage of participants with any adverse event · patients undergoing knee arthroscopy
Morphine showed no clear difference in adverse eventsPercentage of participants with any adverse event compared with NSAIDs (moderate certainty).
1 finding from 1 review
Resolution at 12 to 24 weeks Quinell Grade (range 0 to 4, resolved disease is grade 0) · adults (> 18 years of age) with trigger finger
NSAID injection showed no clear difference in resolution at 12 to 24 weeks Quinell Grade (range 0 to 4, resolved… compared with glucocorticoid injection (low certainty).
1 finding from 1 review
Persistent moderate to severe symptoms at 12 to 24 weeks · adults (> 18 years of age) with trigger finger
NSAID injection may leads to higher persistent moderate to severe symptoms at 12 to 24 weeks compared with glucocorticoid injection (low certainty).
1 finding from 1 review